ABBV80.BK AbbVie Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 0.69%
- Fundamental score
- -
Is ABBV80.BK undervalued?
Graham numberThe Graham number of AbbVie Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AbbVie Inc. fundamental analysis
No fundamental analysis for AbbVie Inc. yet.
AbbVie Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung canc…
Full company profileFinancial statements of AbbVie Inc. are not available yet.
AbbVie Inc. dividends
AbbVie Inc. has not paid dividends in the last 3 fiscal years.
Who owns AbbVie Inc.
Ownership data of AbbVie Inc. is not available yet.
AbbVie Inc. company profile
- Company name
- AbbVie Inc.
- Ticker
- ABBV80.BK
- Exchange
- Thailand Exchange
- Sector
- -
- Industry
- -
- Employees
- 57,000
- Fiscal year end
- December
- Address
- 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
- Phone
- 847 932 7900
- Website
- abbvie.com
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc. management
10- Mr. Robert A. Michael CPACEO & Chairman of the Board · born 1970
- Mr. Scott T. ReentsExecutive VP & CFO · born 1967
- Dr. Azita Saleki Ph.D.Executive VP & COO · born 1963
- Dr. Roopal B. Thakkar M.D.Executive VP of Research & Development and Chief Scientific Officer · born 1972
- Mr. Jeffrey Ryan StewartExecutive VP & Chief Commercial Officer · born 1969
- Ms. Linda RaySenior VP & Chief Information Officer
- Ms. Elizabeth SheaSenior Vice President of Investor Relations
- Mr. Perry C. SiatisExecutive VP, General Counsel & Secretary · born 1975
- Mr. Demetris D. CrumExecutive VP & Chief Human Resources Officer · born 1981
- Mr. Wulff-Erik von BorckeSenior VP & President of Oncology